Increases in both CD4+ and CD8+ tumor-infiltrating lymphocytes (TILs) were observed post-combination hydrogel treatment, with no significant difference of Tregs in tumors receiving different treatments (Fig. 3d, e, Supplementary Fig. 11f). The gene discussed is CD8A; the disease is neoplasm.